Drug intelligence / Profile preview

BRE-NA01

Development stage: Preclinical
Lead developer: Brexogen
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BRE-NA01 is an exosome-based cell-free regenerative medicine therapeutic being developed by Brexogen for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Utilizing the proprietary BG-Platform, BRE-NA01 consists of therapeutic cargo-controlled exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs). These exosomes are engineered to contain specific biomacromolecules optimized to address the underlying pathology of MASH, offering a regenerative approach without the complexities or safety concerns associated with live cell therapies. The drug is currently in the preclinical stage of development.

Beyond the preview

Go deeper on BRE-NA01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRE-NA01.

Explore the full profile